VitalDecades Guides & Explainers

Weight and metabolism· Sep 24, 2026 ·11 min

Zepbound vs Wegovy: the head-to-head trial, the labels and the price

SURMOUNT-5 (NEJM, 2025) randomized 751 adults with obesity and no type 2 diabetes to tirzepatide or semaglutide at the maximum tolerated dose for 72 weeks: mean weight loss 20.2 percent against 13.7, waist 18.4 cm against 13.0. It was open-label and Lilly-funded. The labels share their core warnings, nausea led each drug's own trials, and neither label allows a cross-trial side-effect comparison. Cash: Zepbound KwikPen $299 to $699 a month by dose, $449 on 7.5 mg and up with refills within 45 days; Wegovy pen $199 for two new-patient fills, then $349 ($399 for 7.2 mg).

Weight and metabolism· Sep 24, 2026 ·11 min

What happens when you stop Ozempic: the trials that measured it

In the STEP 1 extension, people who lost 17.3 percent on semaglutide 2.4 mg regained 11.6 percentage points in the year after stopping, about two thirds of the loss, and their cardiometabolic gains reverted toward baseline. In SURMOUNT-4, switching from tirzepatide to placebo meant a 14 percent regain from week-36 weight over 52 weeks against a further 5.5 percent loss on the drug. In STEP 4, placebo regained 6.9 percent from week-20 weight over 48 weeks against a 7.9 percent loss on semaglutide. No trial tested a taper. Semaglutide's half-life is about a week, tirzepatide's about five days.

Weight and metabolism· Sep 24, 2026 ·11 min

Wegovy pill vs injection: what one label says about both

The Wegovy tablet (25 mg daily) and injection (2.4 mg weekly) share one label. In adults without type 2 diabetes the label says their average semaglutide levels are similar, but the tablet is 1 to 2 percent absorbed and must be taken on an empty stomach with up to 4 ounces of water, 30 minutes before anything else. Its trial: 13.6 percent mean weight loss at 64 weeks against 2.4 on placebo. The injection's: 14.9 percent at 68 weeks against 2.4. In type 2 diabetes the tablet is unstudied for weight loss and gives lower levels. Self-pay: pill from $149 a month, pen $199 for two fills then $349.

Sponsored

3.3/5 our score

• One flat price at every dose: $175 monthly down to $99 on a 12-month prepay
• Names its prescriber network (Arora Health) and its compounding pharmacies

Compounded semaglutide from $99/mo on a 12-month prepay; $175 month to month

Sells compounded semaglutide and tirzepatide, which are not FDA-approved products.

See plans Read our review

Affiliate link, we may earn a commission at no extra cost to you.

Weight and metabolism· Sep 24, 2026 ·11 min

Ozempic cost without insurance in 2026: Novo's own prices, dose by dose

Novo's self-pay offer prices the Ozempic pen at $349 a month (0.25 to 1 mg) and $499 (2 mg), with $199 for new patients' first two fills through December 31, 2026, and the pill at $149, $199 or $299 by dose. List price is $1,027.51 per pen or bottle, and the pen's falls to $675 on January 1, 2027; self-pay prices do not change. With commercial coverage the card takes the copay to as little as $25 (the card saves at most $100 a month); government beneficiaries are excluded. Every offer requires an on-label prescription, and the label is type 2 diabetes.

Weight and metabolism· Sep 24, 2026 ·13 min

GLP-1 side effects: what the labels report, drug by drug

From the Wegovy, Zepbound and Foundayo labels: nausea in 44, 25 to 29 and 26 to 35 percent of people against 16, 8 and 10 on placebo, mostly during dose escalation; 6.8, 4.8 to 6.7 and 6 to 10 percent stopped for side effects against about 3 on placebo. Serious events are rare and measured: pancreatitis at 0.14 to 0.2 cases per 100 patient-years, gallstones in 1 to 2.5 percent, acute kidney injury in 0.2 to 0.5 percent on Zepbound and Foundayo. The boxed warning is thyroid C-cell tumors in rodents, unknown in humans. The labels name the symptoms that mean stop and call.

Weight and metabolism· Sep 22, 2026 ·15 min

Does Ozempic cause hair loss? What the labels and the 2026 studies say

The Wegovy label reports hair loss in 3.3 percent of adults on 2.4 mg versus 1 percent on placebo, and 5.8 percent at 7.2 mg, with the rate in women several times the rate in men (8.4 versus 0.2 percent). Zepbound and Foundayo report 4 to 5 percent with the same split. A July 2026 BMJ cohort in type 2 diabetes found a 37 to 68 percent higher hazard than other diabetes drugs at about 7 versus 4 to 5 cases per 1,000 person-years; a September 2026 genetic study points at the receptor itself in predisposed men. Shedding after a trigger regrows within six to nine months, per the AAD.

Weight and metabolism· Sep 3, 2026 ·10 min

Does Medicare cover GLP-1 weight loss drugs? The 2026 rules

Part D still cannot pay for a drug prescribed for weight loss, and that has not changed. What changed on July 1, 2026 is that a separate program, the Medicare GLP-1 Bridge, began offering three specific products for a $50 monthly copay outside the Part D benefit. The list is narrower than it sounds, and the $50 does not count toward your out-of-pocket cap.

Weight and metabolism· Sep 3, 2026 ·8 min

GLP-1 friendly foods: what to eat when the drug has taken your appetite

On a GLP-1 the binding constraint is not which foods you choose, it is how little food you can face. Semaglutide's own label reports nausea in 44 percent of people and constipation in 24 percent, and the drug delays gastric emptying. Eat protein first, keep fat modest at any single sitting, and treat fluid and fiber as scheduled, not incidental.

Weight and metabolism· Sep 4, 2026 ·15 min

Intermittent fasting: what happens when you match the calories

In a controlled-feeding trial where both groups ate identical calories, time-restricted eating produced a 0.3 kg difference. Cochrane's 2026 review found no meaningful advantage over standard advice. The lean mass concern is real but overstated, and no randomized trial has ever measured a hard outcome.

Sponsored

3.3/5 our score

• One flat price at every dose: $175 monthly down to $99 on a 12-month prepay
• Names its prescriber network (Arora Health) and its compounding pharmacies

Compounded semaglutide from $99/mo on a 12-month prepay; $175 month to month

Sells compounded semaglutide and tirzepatide, which are not FDA-approved products.

See plans Read our review

Affiliate link, we may earn a commission at no extra cost to you.

Weight and metabolism· Sep 3, 2026 ·7 min

What Wegovy and Zepbound cost without insurance in 2026

Manufacturer self-pay prices as of 2026-08-19: Wegovy tablets $149 to $299 a month; Wegovy pen $199 for the first two months (new patients) then $349, or $399 for Wegovy HD; Zepbound $299 (2.5 mg), $399 (5 mg), $449 for 7.5 to 15 mg if refilled within 45 days, otherwise $499 to $699; Foundayo $149 to $299; Mounjaro $499. List prices are $1,349 (Wegovy) and $499 to $1,086 (Zepbound). Commercial-insurance savings cards bring covered patients to $25.

Weight and metabolism· Sep 18, 2026 ·6 min

Metabolic health after 40: the numbers to know

The metabolic numbers with published thresholds: blood pressure (normal under 120/80; stage 1 hypertension from 130/80, per the 2025 AHA/ACC guideline), fasting glucose and A1C (prediabetes from 100 mg/dL and 5.7%), LDL cholesterol (optimal under 100 mg/dL), triglycerides (normal under 150), HDL (low under 40 men, 50 women), waist (over 40 inches men, 35 women is high risk) and BMI. Screening for prediabetes starts at 35 with overweight; the statin discussion at 40.

Weight and metabolism· Sep 24, 2026 ·8 min

GLP-1 medications compared: Wegovy, Zepbound and the pills

For weight: Wegovy injection (weekly; 1.7 or 2.4 mg, or 7.2 mg Wegovy HD), Wegovy tablets (25 mg daily), Zepbound (weekly tirzepatide, 5 to 15 mg) and Foundayo (orforglipron pill, up to 17.2 mg daily). For type 2 diabetes: Ozempic, Mounjaro, Rybelsus. Label trial results range from about 7% (Saxenda) to 21% (Zepbound 15 mg) mean weight loss versus 2 to 4% on placebo. Self-pay prices run $149 to $699 a month.

Weight and metabolism· Sep 3, 2026 ·7 min

Does insurance cover GLP-1s? Medicare, Medicaid, employers

As of August 2026: Medicare Part D still cannot cover drugs used solely for weight loss by statute, but the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) gives eligible beneficiaries Wegovy, Wegovy tablets, Zepbound KwikPen or Foundayo for a $50 copay; Wegovy is Part D-coverable for its cardiovascular indication. Thirteen state Medicaid programs covered GLP-1s for obesity in January 2026 (KFF). Around 43 to 49% of large employers cover them for weight loss.

Weight and metabolism· Sep 4, 2026 ·8 min

Compounded semaglutide and tirzepatide: what the FDA says

Compounded semaglutide and tirzepatide are not FDA-approved: the FDA does not review them for safety, effectiveness or quality. The drug shortages that allowed mass compounding were declared over in December 2024 (tirzepatide) and February 2025 (semaglutide). Since September 2025 the FDA has warned 113 telehealth sellers about false claims. Check the pharmacy license and the warning-letter database before you buy.